Arbutus Biopharma announced that Tram Tran, MD has notified the company of her intention to resign from the company’s Board of Directors, effective February 26. Dr. Tran will be transitioning into public service commencing February 27, 2023, that will preclude her participation on the Arbutus and other pharmaceutical and biotechnology Boards. Tran joined the Arbutus Board of Directors in November 2021 and served as a member of the Executive Compensation and Human Resources Committee. Tran’s decision to resign is not due to any disagreement with the Company on any matter relating to the company’s operations, policies or practices. The company will immediately begin a search for a new independent board member to replace Tran.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABUS:
- Arbutus Announces Resignation of Board Member
- Arbutus Biopharma announces 2023 corporate objectives
- Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
- Arbutus Biopharma completes enrollment in Phase 2 trial with AB-729, NA therapy
- Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection
